Targeting FGL1 has shown preclinical efficacy in enhancing immunotherapy involving programmed death ligand 1 (PD-L1)/PD-1 checkpoint blockade, inhibiting liver metastasis and relieving autoimmunity without overt hepatotoxicity. Here, FGL1 is linked to Autoimmunity.